Trial Profile
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB ADMINISTERED IN COMBINATION WITH LETROZOLE VS. LETROZOLE ALONE AS FIRST LINE THERAPY IN POST-MENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/PR+/HER2- BREAST CANCER
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 30 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 17 Mar 2012 Planned number of patients changed from 16 to 250 as reported by European Clinical Trials Database record.
- 19 Apr 2011 Actual patient number is 16 as reported by ClinicalTrials.gov.